Engineering nanomedicines to overcome multidrug resistance in cancer therapy

Giovanni L. Beretta, Francesca Cavalieri

Research output: Contribution to journalArticle

Abstract

Drug resistance to conventional antitumor drugs represents one of the major causes of treatment failure in patients affected by tumors. Two main types of drug resistance to anticancer drugs are found in tumors, namely intrinsic resistance, in which tumor cells are inherently resistant to chemotherapy, and acquired resistance, which results from previous drug exposure. Tumor cells resistant to a chemotherapeutic agent become cross-resistant to both similar and structurally unrelated classes of antitumor drugs, a biological mechanism known as multi drug resistance (MDR). Among the strategies considered to overcome MDR, nanovector-mediated drug administration represents an innovative and promising alternative. In this review, we report a number of nanovectors including polymer-drug conjugates, polymeric micelles, nanotubes, LbL nanocapsules, and silica and gold nanoparticles. These systems are designed for the efficient delivery of anthracyclines, vinca alkaloids, taxanes, and others drugs. The development of these nanovectos to specifically overcome MDR and their mechanisms of action are covered and discussed. Finally, we discuss challenges and opportunities for further development of nanodevices-based chemotherapies to circumvent MDR through the design of nanovectors for the delivery of multiple cargoes.

Original languageEnglish
Pages (from-to)3-22
Number of pages20
JournalCurrent Medicinal Chemistry
Volume23
Issue number1
Publication statusPublished - Jan 1 2016

Fingerprint

Nanomedicine
Medical nanotechnology
Multiple Drug Resistance
Pharmaceutical Preparations
Neoplasms
Drug Resistance
Antineoplastic Agents
Tumors
Nanocapsules
Vinca Alkaloids
Therapeutics
Drug Therapy
Nanotubes
Taxoids
Anthracyclines
Chemotherapy
Micelles
Treatment Failure
Silicon Dioxide
Gold

Keywords

  • Anticancer therapy
  • Drug-resistant cancer
  • Multi drug resistance
  • Nanodrug delivery
  • NIR responsive nanodrugs
  • Nucleic acid delivery
  • ROS responsive nanodrugs

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Engineering nanomedicines to overcome multidrug resistance in cancer therapy. / Beretta, Giovanni L.; Cavalieri, Francesca.

In: Current Medicinal Chemistry, Vol. 23, No. 1, 01.01.2016, p. 3-22.

Research output: Contribution to journalArticle

Beretta, Giovanni L. ; Cavalieri, Francesca. / Engineering nanomedicines to overcome multidrug resistance in cancer therapy. In: Current Medicinal Chemistry. 2016 ; Vol. 23, No. 1. pp. 3-22.
@article{3aa071905b694d19bf507042959c38e7,
title = "Engineering nanomedicines to overcome multidrug resistance in cancer therapy",
abstract = "Drug resistance to conventional antitumor drugs represents one of the major causes of treatment failure in patients affected by tumors. Two main types of drug resistance to anticancer drugs are found in tumors, namely intrinsic resistance, in which tumor cells are inherently resistant to chemotherapy, and acquired resistance, which results from previous drug exposure. Tumor cells resistant to a chemotherapeutic agent become cross-resistant to both similar and structurally unrelated classes of antitumor drugs, a biological mechanism known as multi drug resistance (MDR). Among the strategies considered to overcome MDR, nanovector-mediated drug administration represents an innovative and promising alternative. In this review, we report a number of nanovectors including polymer-drug conjugates, polymeric micelles, nanotubes, LbL nanocapsules, and silica and gold nanoparticles. These systems are designed for the efficient delivery of anthracyclines, vinca alkaloids, taxanes, and others drugs. The development of these nanovectos to specifically overcome MDR and their mechanisms of action are covered and discussed. Finally, we discuss challenges and opportunities for further development of nanodevices-based chemotherapies to circumvent MDR through the design of nanovectors for the delivery of multiple cargoes.",
keywords = "Anticancer therapy, Drug-resistant cancer, Multi drug resistance, Nanodrug delivery, NIR responsive nanodrugs, Nucleic acid delivery, ROS responsive nanodrugs",
author = "Beretta, {Giovanni L.} and Francesca Cavalieri",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "23",
pages = "3--22",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Engineering nanomedicines to overcome multidrug resistance in cancer therapy

AU - Beretta, Giovanni L.

AU - Cavalieri, Francesca

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Drug resistance to conventional antitumor drugs represents one of the major causes of treatment failure in patients affected by tumors. Two main types of drug resistance to anticancer drugs are found in tumors, namely intrinsic resistance, in which tumor cells are inherently resistant to chemotherapy, and acquired resistance, which results from previous drug exposure. Tumor cells resistant to a chemotherapeutic agent become cross-resistant to both similar and structurally unrelated classes of antitumor drugs, a biological mechanism known as multi drug resistance (MDR). Among the strategies considered to overcome MDR, nanovector-mediated drug administration represents an innovative and promising alternative. In this review, we report a number of nanovectors including polymer-drug conjugates, polymeric micelles, nanotubes, LbL nanocapsules, and silica and gold nanoparticles. These systems are designed for the efficient delivery of anthracyclines, vinca alkaloids, taxanes, and others drugs. The development of these nanovectos to specifically overcome MDR and their mechanisms of action are covered and discussed. Finally, we discuss challenges and opportunities for further development of nanodevices-based chemotherapies to circumvent MDR through the design of nanovectors for the delivery of multiple cargoes.

AB - Drug resistance to conventional antitumor drugs represents one of the major causes of treatment failure in patients affected by tumors. Two main types of drug resistance to anticancer drugs are found in tumors, namely intrinsic resistance, in which tumor cells are inherently resistant to chemotherapy, and acquired resistance, which results from previous drug exposure. Tumor cells resistant to a chemotherapeutic agent become cross-resistant to both similar and structurally unrelated classes of antitumor drugs, a biological mechanism known as multi drug resistance (MDR). Among the strategies considered to overcome MDR, nanovector-mediated drug administration represents an innovative and promising alternative. In this review, we report a number of nanovectors including polymer-drug conjugates, polymeric micelles, nanotubes, LbL nanocapsules, and silica and gold nanoparticles. These systems are designed for the efficient delivery of anthracyclines, vinca alkaloids, taxanes, and others drugs. The development of these nanovectos to specifically overcome MDR and their mechanisms of action are covered and discussed. Finally, we discuss challenges and opportunities for further development of nanodevices-based chemotherapies to circumvent MDR through the design of nanovectors for the delivery of multiple cargoes.

KW - Anticancer therapy

KW - Drug-resistant cancer

KW - Multi drug resistance

KW - Nanodrug delivery

KW - NIR responsive nanodrugs

KW - Nucleic acid delivery

KW - ROS responsive nanodrugs

UR - http://www.scopus.com/inward/record.url?scp=84959294168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959294168&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84959294168

VL - 23

SP - 3

EP - 22

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 1

ER -